LIGHT INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE

被引：0
|
作者：
Brunetti, G. [1 ]
Rizzi, R. [2 ]
Gigante, I. [1 ]
Oranger, A. [1 ]
Mori, G. [3 ]
Carbone, C. [1 ]
Mongelli, T. [1 ]
Scardino, S. [2 ]
Daraia, B. [2 ]
Curci, P. [2 ]
Mestice, A. [2 ]
Zallone, A. [1 ]
Colucci, S. [1 ]
Specchia, G. [2 ]
Grano, M. [1 ]
机构：
[1] Univ Bari, Sect Human Anat & Histol, Dept Basic & Med Sci Neurosci & Sense Organs, Bari, Italy
[2] Univ Bari, Sect Hematol Transplantat, Dept Emergency & Organ Transplantat, Bari, Italy
[3] Univ Foggia, Foggia, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1622
引用
收藏
页码：628 / 629
页数：2
相关论文
共 50 条
  • [1] LIGHT/TNFSF14 INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE
    Rizzi, R.
    Brunetti, G.
    Oranger, A.
    Gigante, I.
    Mongelli, T.
    Gagliardi, V. P.
    Mestice, A.
    Curci, P.
    Colucci, S.
    Specchia, G.
    Grano, M.
    HAEMATOLOGICA, 2015, 100 : 157 - 157
  • [2] A role for immunoglobulins in the osteolytic bone disease of multiple myeloma
    Westhrin, Marita
    Kovcic, Vlado
    Bondt, Albert
    Holst, Stephanie
    Zhang, Zeijan
    Slordahl, Tobias
    Sundan, Anders
    Waage, Anders
    Wuhrer, Manfred
    Standal, Therese
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 341 - 341
  • [3] Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
    Croucher, PI
    Shipman, CM
    Perry, M
    Lippitt, J
    Asosingh, K
    van Beek, EJR
    Van Camp, B
    Russell, RGG
    Dunstan, C
    Vanderkerken, K
    BONE, 2001, 28 (05) : S81 - S81
  • [4] Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
    Croucher, PI
    Shipman, CM
    Lippitt, J
    Perry, M
    Asosingh, K
    Hijzen, A
    Brabbs, AC
    van Beek, EJR
    Holen, I
    Skerry, TM
    Dunstan, CR
    Russell, GR
    Van Camp, B
    Vanderkerken, K
    BLOOD, 2001, 98 (13) : 3534 - 3540
  • [5] Identification of new targets for therapy of osteolytic bone disease in multiple myeloma
    Hjertner, O
    Standal, T
    Borset, A
    Sundan, A
    Waage, A
    CURRENT DRUG TARGETS, 2005, 6 (06) : 701 - 711
  • [6] Targeting CCR1 for the treatment of osteolytic bone disease in multiple myeloma
    Vallet, Sonia
    Raje, Noopur
    Fulciniti, Maria Teresa
    Ishitsuka, Kenji
    Hideshima, Teru
    Podar, Klaus
    Pozzi, Samanatha
    Breitkreutz, Iris
    Kiziltepe, Tanyel
    Okawa, Yutaka
    Ikeda, Hiroshi
    Santo, Loredana
    Mukherjee, SIddhartha
    Vaghela, Nileshwari
    Cirstea, Diana
    Boccadoro, Mario
    Anderson, Kenneth C.
    BLOOD, 2007, 110 (11) : 738A - 738A
  • [7] Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease
    E Terpos
    J Berenson
    R J Cook
    A Lipton
    R E Coleman
    Leukemia, 2010, 24 : 1043 - 1049
  • [8] Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease
    Terpos, E.
    Berenson, J.
    Cook, R. J.
    Lipton, A.
    Coleman, R. E.
    LEUKEMIA, 2010, 24 (05) : 1043 - 1049
  • [9] SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
    Heusschen, Roy
    Muller, Josephine
    Binsfeld, Marilene
    Marty, Caroline
    Plougonven, Erwan
    Dubois, Sophie
    Mahli, Nadia
    Moermans, Karen
    Carmeliet, Geert
    Leonard, Angelique
    Baron, Frederic
    Beguin, Yves
    Menu, Eline
    Cohen-Solal, Martine
    Caers, Jo
    ONCOTARGET, 2016, 7 (21) : 30712 - 30729
  • [10] The receptor tyrosine kinase Mer promotes multiple myeloma progression and osteolytic bone disease
    Engelmann, J.
    Ben Batalla, I.
    Taipaleenmaeki, H.
    Riecken, K.
    Gensch, V.
    Paesler, S.
    Berenbrok, N.
    Vargas, M. E.
    Waizenegger, J.
    Fehse, B.
    Pantel, K.
    Darwish, I.
    Bhamidipati, S.
    Masuda, E.
    Bokemeyer, C.
    Hesse, E.
    Loges, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 190 - 190
12345